H.C. Wainwright & Co. is acting as the exclusive placement agent for the transaction. The transaction is expected to close on or about July 26, 2024, subject to satisfaction of customary closing conditions. The Company intends to use the net proceeds from the transaction, coupled with an additional $3.58 million in net proceeds raised in May 2024 through the Company's at-the-market facility, for working capital and other general corporate purposes. This press release does not constitute an offer to sell or ...

PITTSBURGH, July 26, 2024 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug discovery and biologics, today announced that it has entered into a definitive agreement for the exercise of certain existing warrants to purchase an aggregate of 958,117 shares of its common stock having a current exercise price of $14.00 originally issued in February 2021, June 2021 and May 2022, at a reduced exercise price of $1.32 per share. The issuance and/or resale of the shares of common ...

GPCRs are cell surface membrane receptors that are believed to play a key role in tumorigenesis, with prior studies demonstrating involvement in cancer initiation, progression, and metastasis. It is estimated that drugs targeting GPCRs represent more than 30% of the global market for therapeutic drugs, yet the number of characterized GPCR targets represent just a small fraction of the GPCR superfamily, suggesting significant potential to further target GPCRs for future drug discovery and development2,3. "As ...

Predictive Oncology's organ-specific in vitro models are designed to better mimic the physiological environment of human tissue The 3D cell culture market is projected to grow by more than 14% annually, from $1.4 billion in 2022 to nearly $5.3 billion annually by 20321 PITTSBURGH, June 04, 2024 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug discovery and biologics, today announced the availability of its unique 3D cell culture model to advance cancer drug discovery a ...

Core Insights - Predictive Oncology Inc. has introduced a unique 3D cell culture model aimed at enhancing cancer drug discovery and future drug development [1][4] - The 3D cell culture market is projected to grow from $1.4 billion in 2022 to nearly $5.3 billion by 2032, reflecting a compound annual growth rate (CAGR) of over 14% [1][5] Company Overview - Predictive Oncology is leveraging AI and machine learning to expedite early drug discovery, with a scientifically validated AI platform, PEDAL, that predicts tumor response to drug compounds with 92% accuracy [6] - The company maintains a biobank of over 150,000 assay-capable heterogeneous human tumor samples, providing extensive AI-based drug discovery solutions [6] Industry Context - Organ-specific 3D cell cultures offer a more accurate representation of human tissue architecture compared to traditional 2D assays, improving predictions of clinical outcomes and optimizing candidate selection for clinical development [2][4] - The application of 3D cell cultures spans various fields, including pharmaceuticals, regenerative medicine, cancer research, and toxicology, significantly enhancing the accuracy of drug efficacy, toxicity, and pharmacokinetics predictions [5]

PITTSBURGH, May 28, 2024 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug discovery and biologics, today announced that positive results from a retrospective study that the company recently completed in collaboration with UPMC Magee-Womens Hospital will be presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, which is being held May 31-June 4, 2024, in Chicago, Il. The purpose of the study was to determine if Predictive Oncology could lever ...

Predictive Oncology Inc. (NASDAQ:POAI) Q1 2024 Earnings Call Transcript May 15, 2024 8:30 AM ET Company Participants Glenn Garmont - IR Raymond Vennare - CEO and Chairman Josh Blacher - CFO Operator Ladies and gentlemen, good morning, and thank you for standing by. Welcome to the Predictive Oncology Q1 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speakers’ presentation, there will be an opportunity to ask your questions. Please be advised that today's co ...

Financial Performance - Predictive Oncology reported a net loss of approximately $4.2 million on total revenue of approximately $0.4 million for Q1 2024, compared to a net loss of $3.4 million in Q1 2023[1][14] - Revenue for Q1 2024 was $419,646, representing a 75% increase from $239,895 in the same period of 2023[8][14] - Gross profit margin improved to approximately 55% in Q1 2024, up from 50% in Q1 2023, primarily due to a change in sales mix[8][14] - Basic and diluted net loss per common share for Q1 2024 was $(1.04), compared to $(0.86) for Q1 2023[8][14] Cash and Liabilities - The company ended Q1 2024 with $5.2 million in cash, down from $8.7 million as of December 31, 2023[8][11] - Total liabilities increased to $6.5 million as of March 31, 2024, compared to $6.1 million as of December 31, 2023[8][11] Expenses - General and administrative expenses increased to $2.6 million in Q1 2024 from $2.3 million in Q1 2023, mainly due to higher professional fees[8][14] Collaborations and Research - Predictive Oncology is collaborating with Fujifilm to enhance drug safety by improving bacterial endotoxin testing, utilizing its EndoPrep™ technology[4] - The company is making progress on a $6.2 million Phase 2b grant for a novel intranasal flu vaccine in collaboration with FluGen[4] - An abstract from a study with UPMC Magee-Womens Hospital has been accepted for presentation at the ASCO 2024 Annual Meeting, focusing on machine learning models predicting survival outcomes in ovarian cancer patients[4]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Delaware 33-1007393 (State or other jurisdiction of (I.R.S. Employer incorporation or organization) Identification No.) 91 43rd Street, Suite 110 Pittsburgh, Pennsylvania 15201 (Address of ...

Predictive Oncology Inc. (NASDAQ:POAI) Q4 2023 Earnings Conference Call April 1, 2024 8:30 AM ET Company Participants Glenn Garmont - IR Raymond F. Vennare - CEO and Chairman Josh Blacher - Interim CFO Conference Call Participants Operator Greetings and welcome to the Predictive Oncology Fourth Quarter 2023 Earnings Call. At this time, all participants are in a listen-only mode. A brief question-and-answer session will follow the formal presentation. [Operator Instructions]. As a reminder this conference is ...